

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

MDA-MB-435S

RRID:CVCL_0622

Type: Cell Line

Proper Citation

RRID:CVCL_0622

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0622

Proper Citation: RRID:CVCL_0622

Description: Cell line MDA-MB-435S is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: [PMID:2007622](#), [PMID:10700188](#), [PMID:12354931](#), [PMID:12661003](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:26589293](#), [PMID:28940260](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-435S

Synonyms: MDA-MB-435s, MDA-MB-435 S, MDA-MB-435-S, MDAMB435S, BrCL15

Cross References: BTO:BTO_0003941, CLO:CLO_0007638, CLDB:cl7142, ArrayExpress:E-MTAB-2770, ATCC:HTB-129, BCRJ:0165, BioGRID_ORCS_Cell_line:567, BioSample:SAMN10987989, cancercellines:CVCL_0622, CCRID:1101HUM-PUMC000015, CCRID:3101HUMTCHu36, CCTCC:GDC0053, Cell_Model_Passport:SIDM01222, ChEMBL-Cells:ChEMBL4483174, ChEMBL-

Targets:CHEMBL4483284, CLS:300277, Cosmic:809237, Cosmic:871155, Cosmic:894089, Cosmic:904381, Cosmic:1044202, Cosmic:1046951, Cosmic:1287922, Cosmic:1289399, Cosmic:1523969, Cosmic:1609477, Cosmic:2301531, DepMap:ACH-000884, GEO:GSM149983, GEO:GSM149991, GEO:GSM149999, GEO:GSM421877, GEO:GSM887298, GEO:GSM888373, GEO:GSM1374657, ICLC:HTL03006, KCB:KCB 200773YJ, LiGeA:CCLE_408, LINCS_HMS:50030, LINCS_LDP:LCL-1307, PRIDE:PXD016837, Progenetix:CVCL_0622, PubChem_Cell_line:CVCL_0622, Wikidata:Q54904637

ID: CVCL_0622

Hierarchy: cvcl_0417

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260829T234602+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-435S.

Warning: Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565.

Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.. **Warning:** Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565.

Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chen Y, et al. (2026) Ceritinib induces ferroptosis via TRIM21-mediated GLUT1 ubiquitination and AMPK-driven metabolic reprogramming in breast cancer. *iScience*, 29(6), 115846.

Blackman SA, et al. (2026) Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. *The Journal of biological chemistry*, 302(6), 111476.

Rasbach E, et al. (2025) Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. *Molecular cancer*, 24(1), 310.

Shin S, et al. (2025) mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport. *Molecular cell*, 85(18), 3486.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Dilasser F, et al. (2025) A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer. *Cell reports. Medicine*, 6(7), 102233.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. *Cancer discovery*, 14(12), 2450.

Sandor LF, et al. (2024) De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis. *Cell reports*, 43(3), 113936.

Zhang W, et al. (2023) AEP-cleaved DDX3X induces alternative RNA splicing events to mediate cancer cell adaptation in harsh microenvironments. *The Journal of clinical investigation*, 134(3).

Li H, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. *Cancer cell*, 40(1), 36.

Matas-Rico E, et al. (2021) Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8⁺ T cells. *Cell reports*, 37(7), 110013.

Yoon SO, et al. (2017) Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition. *Molecular cell*, 67(3), 512.

Pal D, et al. (2017) TGF- β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44⁺/CD24⁻ cancer cells. *eLife*, 6.